BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19918062)

  • 1. HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.
    Dai B; Yang L; Yang H; Hu B; Baltimore D; Wang P
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20382-7. PubMed ID: 19918062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.
    Dai B; Xiao L; Bryson PD; Fang J; Wang P
    Mol Ther; 2012 Sep; 20(9):1800-9. PubMed ID: 22588271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Immune Responses against HIV-1 with Adenovector (Gag and Tat) Prime/Protein Boost Regimen and GM-CSF Injection.
    Hosseini Rouzbahani N; Bayanolhagh S; Gholami M; Esmaeilzadeh A; Bayat Jozani Z; Mohraz M; Pourfathollah AA
    Iran J Allergy Asthma Immunol; 2016 Oct; 15(5):403-412. PubMed ID: 27917627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
    Wanjalla CN; Faul EJ; Gomme EA; Schnell MJ
    Vaccine; 2010 Dec; 29(1):130-40. PubMed ID: 20728525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.
    Chege GK; Burgers WA; Stutz H; Meyers AE; Chapman R; Kiravu A; Bunjun R; Shephard EG; Jacobs WR; Rybicki EP; Williamson AL
    J Virol; 2013 May; 87(9):5151-60. PubMed ID: 23449790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
    Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
    Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.
    Li M; Jiang Y; Xu C; Zhang Z; Sun X
    Int J Nanomedicine; 2013; 8():1843-54. PubMed ID: 23690682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
    Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
    Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.
    Rosati M; Alicea C; Kulkarni V; Virnik K; Hockenbury M; Sardesai NY; Pavlakis GN; Valentin A; Berkower I; Felber BK
    Vaccine; 2015 Apr; 33(18):2167-74. PubMed ID: 25802183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.
    Hou J; Zhang Q; Liu Z; Wang S; Li D; Liu C; Liu Y; Shao Y
    Hum Vaccin Immunother; 2016; 12(2):545-53. PubMed ID: 26305669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
    Trumpfheller C; Finke JS; López CB; Moran TM; Moltedo B; Soares H; Huang Y; Schlesinger SJ; Park CG; Nussenzweig MC; Granelli-Piperno A; Steinman RM
    J Exp Med; 2006 Mar; 203(3):607-17. PubMed ID: 16505141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.